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ARTICLE
Restriction of essential amino acids dictates
the systemic metabolic response to dietary
protein dilution
Yann W. Yap1,15, Patricia M. Rusu 1,15, Andrea Y. Chan1, Barbara C. Fam2, Andreas Jungmann3,4,
Samantha M. Solon-Biet 5, Christopher K. Barlow6, Darren J. Creek6,7, Cheng Huang 6,
Ralf B. Schittenhelm 6, Bruce Morgan 8, Dieter Schmoll9, Bente Kiens 10, Matthew D. W. Piper11,
Mathias Heikenwälder12, Stephen J. Simpson 5, Stefan Bröer 13, Sofianos Andrikopoulos2,
Oliver J. Müller 4,14 & Adam J. Rose 1✉
Dietary protein dilution (DPD) promotes metabolic-remodelling and -health but the precise
nutritional components driving this response remain elusive. Here, by mimicking amino acid
(AA) supply from a casein-based diet, we demonstrate that restriction of dietary essential
AA (EAA), but not non-EAA, drives the systemic metabolic response to total AA deprivation;
independent from dietary carbohydrate supply. Furthermore, systemic deprivation of threo-
nine and tryptophan, independent of total AA supply, are both adequate and necessary to
confer the systemic metabolic response to both diet, and genetic AA-transport loss, driven
AA restriction. Dietary threonine restriction (DTR) retards the development of obesity-
associated metabolic dysfunction. Liver-derived fibroblast growth factor 21 is required for the
metabolic remodelling with DTR. Strikingly, hepatocyte-selective establishment of threonine
biosynthetic capacity reverses the systemic metabolic response to DTR. Taken together, our
studies of mice demonstrate that the restriction of EAA are sufficient and necessary to confer
the systemic metabolic effects of DPD.
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The current classification of essential amino acids (EAA) isbased on the nutritional requirements for growth andvitality under nil dietary supply of an amino acid (AA)1.
However, humans rarely face dramatic protein/AA insufficiency,
and for the first time in human history, nutritional excesses mean
the amount of overweight people outnumber the amount of
underweight people on a global scale2. This calls for a reconsi-
deration of AA functions in nutrition, now based upon health-
related criteria. One approach is dietary protein dilution (DPD),
where protein is reduced and replaced by other nutrient sources,
and is distinct from caloric restriction3–6. Unlike severe protein/
AA restriction, which is not compatible with vitality, moderate
DPD promotes longevity in multiple species including flies7–9,
rodents4,10,11, and perhaps humans12. Furthermore, DPD also
affects health-span and preclinical studies have demonstrated that
DPD can retard age-related diseases such as cancer12,13, type 2
diabetes14,15, and dyslipidemia/fatty liver disease16,17. Notably,
dietary protein intake rates are positively related to type 2 dia-
betes risk as well as all-cause mortality in humans18,19.
While metabolic health and longevity pursuant to DPD is likely
to involve numerous mechanisms, it was recently demonstrated
that DPD promotes metabolic and physiological adaptations via
constituent AA14,20,21, which is largely mimicked by a genetic
deficiency in intestinal and kidney neutral AA transport22. In
particular, dietary protein or AA restriction promotes such
metabolic remodelling and health by the liver-derived hormone
fibroblast growth factor 21 (FGF21)23, largely by increasing
energy expenditure relative to food energy intake14,17,24–32.
Importantly, DPD also increases FGF21 in humans14,21,24,33, and
this increase is associated with heightened energy expenditure33
and improved indices of metabolic health14. However, whether
the simultaneous increase in other non-protein/AA nutrients
such as certain carbohydrates34–36 are required for DPD effects,
as well as which particular AA drive this process is currently
debated23,37. On one hand, restriction of EAA such as the
branched chain amino acids21,38–41 and sulfur-containing
AAs42–45, have been shown to be sufficient in conferring the
systemic effects of DPD. On the other hand, others have
demonstrated that altered somatic non-EAA metabolism is suf-
ficient and necessary for DPD effects14,46–49. Here we attempted
to resolve this issue by formally testing which particular amino
acids are required to induce the systemic response to DPD and
show that specific dietary EAA restriction is both sufficient and
necessary to drive the systemic metabolic response to DPD.
Results
EAA restriction dictates the metabolic response to DPD. We
previously demonstrated that DPD improves glucose and lipid
homoeostasis in obesity and that dilution of amino acids (AA)
was sufficient to mimic these effects14,16,49. However, it remained
to be resolved whether the dilution of protein by substituting with
other dietary nutrients (i.e., carbohydrate and fat), and/or which
particular dietary AA, were responsible. To examine this, we fed
mice a protein-restricted diet (5% energy from casein protein)
and compared the effects to a diet where the reduced protein
component was replaced with proteinogenic AA at ratios found
within casein (see Supplementary Tables 1 and 2 for diet com-
positions). This experiment demonstrated that AA add-back
reversed the effects of protein restriction to reduce serum urea
(Fig. 1a), a biomarker of general protein/AA supply, establishing
that the addition of purified amino acids functioned physiologi-
cally as protein equivalents. Furthermore, AA add-back to a
protein-restricted diet reversed the depressed feed efficiency
(Fig. 1b), as calculated from higher body mass gain despite lower
food intake (Supplementary Fig. 1B, C). This altered feed
efficiency was reflected in an opposite pattern in energy expen-
diture (EE; Fig. 1c), as gauged from O2 consumption (Fig. 1d) and
CO2 production (Fig. 1e) rates, with no differences in respiratory
exchange ratio (RER; Supplementary Fig. 1D). The increase in
EE with DPD occurred independently from differences in
body mass during measurement as judged by ANCOVA (Fig. 1f;
adjusted means: NP 0.786 ± 0.005W, LP: 0.955 ± 0.05W, LP+
AA: 0.798 ± 0.04W; LP versus NP or LP+AA: P < 0.001). The
higher EE could not be explained by altered physical activity
(Fig. 1g). Consistent with the notion that increased circulating
FGF21 is obligatory for the effects of DPD to increase
EE14,16,24,26, we found highly elevated levels of blood plasma
FGF21, which were reversed by AA-add back (Fig. 1h). As
increased blood FGF21 levels also confer the effects of DPD
on improved glucose metabolism14,49, we also assessed this
by measuring an index of fasting insulin sensitivity (ISI(f))
(Fig. 1i) from both fasting glucose (Supplementary Fig. 1E) and
insulin (Supplementary Fig. 1F), which correlates well with
improved glucose metabolism with DPD14. The increased ISI(f)
with DPD was indeed completely reversed with AA add-back
(Fig. 1i).
While this experiment demonstrated that AA could be a necessary
component of these effects, dietary carbohydrate was concomitantly
manipulated, and could potentially explain the responses as FGF21 is
affected by certain dietary carbohydrates31,34–36. In addition, the
specific AA conferring the effects of DPD were not identified. As the
liver is an essential organ involved in “sensing” DPD14,26, we initially
investigated the hepatic portal vein (Fig. 2a and Supplementary
File 1) and liver (Fig. 2b and Supplementary File 1) AA levels in
response to DPD. While most nutritional1 EAA were lower in the
portal vein plasma and liver with DPD, certain non-essential AAs
(NEAA) such as Asn, Pro, Glu, and Tyr were also affected meaning
that we had to take a more broader approach than just focussing on
one class of AA. In order to examine this, we conducted a study
where we manipulated the EAA and NEAA specifically, on the basis
of nutritional definitions1,50, and in some diets topping up the
alternate source of AA to keep the total AA supply constant without
altering dietary fat or carbohydrate supply (Fig. 2c). Of note, NEAA
supply positively correlated with urinary and blood serum urea more
so than EAA supply (Fig. 2d and Supplementary Fig. 2A), and there
were non-binary relationships between EAA/NEAA supply and feed
efficiency (Fig. 2e and Supplementary Fig. 2B, C). However, EAA
restriction fully conferred the effects of DPD on EE (Fig. 2f) and
serum FGF21 levels (Fig. 2g). In particular, serum FGF21 levels were
inversely related to total EAA supply (Fig. 2g).
In this study, we also conducted glucose tolerance tests to
further examine diet effects on whole-body metabolism. The
blood glucose excursion (Fig. 2h) and related area under the curve
(Supplementary Fig. 2D) was directly related to EAA supply, with
lower glucose levels found with EAA restriction. Similar results
were seen for that of insulin (Fig. 2i and Supplementary Fig. 2E).
From fasting glucose (Supplementary Fig. 2F) and insulin
(Supplementary Fig. 2G) values, we could calculate various
indices of glucose metabolic control such as the ISI(f) (Fig. 2j) and
HOMA-IR (Supplementary Fig. 2H). In addition, we calculated
the product of the glucose and insulin AUCs (Supplementary
Fig. 2I). Importantly, there were very close correlations between
the indices determined from fasting glucose and insulin
compared with those determined from the glucose tolerance
tests (Supplementary Fig. 2J–L). All of these indices highlighted
that glucose metabolism/insulin sensitivity is heightened with
dietary EAA restriction.
Thr and Trp restriction is necessary for DPD effects. By way of
follow-up, we then sought to determine which particular EAA
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could confer these effects and selected subgroups based upon
known biochemical features50. In particular, we chose one sub-
group based on their classification as ones which cannot be
synthesised by any possible precursor within the mammalian
metabolic network (i.e., strictly metabolically essential; Lys, Thr,
Trp), the branched-chain AA (i.e., Ile, Leu, Val), and the
remaining three (i.e., His, Met, Phe). We then conducted studies
where we added these EAAs back to the low EAA diet and
notably it was only the strictly metabolically essential AA, namely
Lys, Thr, and Trp, which were necessary to confer the systemic
metabolic effects to total EAA deprivation (Fig. 3a–d and Sup-
plementary Fig. 3A–E).
In an attempt to investigate whether a single one of these EAAs
could confer the effects of dietary EAA restriction (DEAR), we
then individually added back either Lys, Thr, or Trp to the EAA
restricted diet and could demonstrate that no single one of these
was necessary for the effects of DEAR (Supplementary Fig. 3F–I).
By logical deduction, this meant that restriction of at least two,
and perhaps all three, of these EAA were necessary for the full
effects of DEAR. To initially test this, we then conducted a study
where we singly restricted Lys, Thr, or Trp, at levels matching
those found in the complete AA restriction, and could
demonstrate that deprivation of either Thr or Trp, but not Lys,
was sufficient to mimic the effects of DEAR (Fig. 3e–h and
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Fig. 1 Dietary amino acids are required for the systemic metabolic effects of dietary protein dilution. a Serum urea levels of mice in response to a 3-
week treatment with diets containing 20% energy from protein (20P), 5% energy from protein (5P), and 5% energy from protein and 15% energy from
amino acids to match that of 20P. Data are mean and SEM; n= 5 individual mice per group. Data were analysed by one-way ANOVA with Holm–Sidak
post-hoc tests. Different than 20P: *P < 0.05, **P < 0.01, ***P < 0.001. Different than 5P: #P < 0.05, ##P < 0.01, ###P < 0.001. b Feed efficiency of mice as in
(a). c Energy expenditure over the different day phases of mice as in (a). d The rate of O2 consumption (VO2) over the different day phases of mice as in
(a). e The rate of CO2 production (VCO2) over the different day phases of mice as in (a). f Scatter plot of energy expenditure (EE) versus body weight of
mice as in (a). g Physical activity as assessed by laser beam breaks across three physical dimensions (sumXYZ) over the different day phases of mice as in
(a). h Serum fibroblast growth factor 21 (FGF21) levels of mice as in (a). i Insulin sensitivity index during fasting (ISI(f)) of mice as in (a).
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Supplementary Fig. 3J–N). Importantly, this finding was
independently supported in separate experiments whereby a diet
low in Met, Thr, and Trp induced feed inefficiency and increased
serum FGF21 similar to DPD (Supplementary Fig. 3O–R).
To test the necessity of the deprivation of these two EAA for
the effects of DEAR, we then conducted studies with selective
add-back of these two EAA in the background of a low total AA
supply, and could demonstrate that deprivation of both Thr and
Trp were required for the systemic metabolic effects of DEAR
(Fig. 3i–l and Supplementary Fig. 3S–W). In summary, in the
background of total dietary protein/AA restriction simultaneously
low levels of Thr and Trp are required for the full effects, whereas
restriction of either Thr or Trp individually can mimic the
majority of effects of DPD.
Our prior studies were done on male mice from 8 weeks of age,
which could potentially limit the applicability of our findings, as
female mice are known to respond differently to dietary
challenges51–53, and such young mice are still growing and thus
may differ in dietary AA requirements compared with adult mice.
Hence, we tested several diets used previously (Figs. 1–3) on 6-
month-old male and female mice for a longer time frame (i.e.,
8 weeks) to assess potential differences (Fig. 4). Moreover, we
tested the effects of total dietary AA restriction (LAA), as well as
EAA (LEAA) and threonine (LT) restriction with matched total
AA supply, on various parameters such as body composition,
metabolic efficiency, and indices of metabolic health. Of note,
while LAA and LEAA caused weight loss (LAA) or weight
stabilisation (LEAA) (Fig. 4a, b), mostly reflected as lean mass
loss, and there was no lean mass loss with LT (Supplementary
Fig. 4A, B). This was reflected by end-point tissue weights, with
both skeletal muscle and heart weights showing a similar trend to
that of lean mass measured by MRI (Fig. 4c, d). Concerning
fatness, mice on all diets gained fat mass, but there were no
statistically significant differences between diets as assessed by
MRI, with the exception of males subjected to LT (Fig. 4a, b).
However, when individual adipose tissue depots were assessed,
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Fig. 2 Dietary essential amino acid restriction, independent from non-essential amino acid or carbohydrate supply, dictates the systemic metabolic
response to dietary protein dilution. a Hepatic portal vein amino acid levels in response to refeeding a low-protein diet following a week of diet adaptation.
Data (mean and SEM) are represented as a proportion of the control group fed a normal protein diet (20%P). n= 5/group derived from samples of
individual mice. Data were analysed by Student’s t-test. Different than 20%P, *P < 0.05. b Liver tissue amino acid levels in response to refeeding a low-
protein diet following a week of diet adaptation. Data are represented as a proportion of the control group fed a normal protein diet (20%P). n= 5/group
derived from samples of individual mice. Data were analysed by Student’s t-test. Different than 20%P, *P < 0.05. c Nutrient source breakdown as %
contribution to total energy for the experimental groups. EAA: essential amino acids. NEAA: non-essential amino acids. d Urinary urea output of mice in
response to a 3-week treatment with diets as per the protocol of SF1A containing nutrient energy sources as in (c). Data are mean and SEM; n= 5
individual mice per group. Data were analysed by one-way ANOVA with Holm–Sidak post-hoc tests. Different than 20P: *P < 0.05, **P < 0.01, ***P < 0.001.
Different than 5P: #P < 0.05, ##P < 0.01, ###P < 0.001. e Feed efficiency of mice as in (d). f Energy expenditure of mice as in (d). g Serum fibroblast growth
factor 21 (FGF21) levels of mice as in (d). h Blood glucose levels during an intraperitoneal glucose tolerance test (ipGTT) of mice as in (d). i Plasma insulin
levels during an intraperitoneal glucose tolerance test (ipGTT) of mice as in (d). j Insulin sensitivity index during fasting (ISI(f)) of mice as in (d).
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both perigonadal and subcutaneous fat depots were lower in
male, but not female, mice subjected to dietary AA/EAA
restriction (Fig. 4c, d). Concerning feed efficiency, the responses
were similar to that of the changes in body weight, with dietary
AA/EAA restriction promoting consistently reduced feed effi-
ciency regardless of sex (Fig. 4e, f). However, LT feeding
produced a consistently higher feed efficiency versus other AA
restriction groups (Fig. 4e, f), probably owing to the less
pronounced effects on lean mass, as there was an equal increase
in EE (Fig. 4g, h) and food E intake (Supplementary Fig. 4C, D) in
all groups subjected to AA/EAA restriction regardless of sex.
Similar to the food E intake and EE responses, serum FGF21
levels were equally higher in mice subjected to AA/EAA
restriction, again regardless of sex (Fig. 4i, j). Glucose metabolism
also showed a similar response, with an equally higher insulin
sensitivity index (Fig. 4k, l), as discerned from fasting blood
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Fig. 3 Certain essential amino acids including threonine and tryptophan are sufficient and necessary for the systemic metabolic effects of dietary
protein dilution. a Feed efficiency of mice in response to a 3-week treatment with diets containing 18% from amino acids (normal amino acid; NAA), 4.5%
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glucose (Supplementary Fig. 4E, F) and plasma insulin (Supple-
mentary Fig. 4G, H), in groups subjected to dietary AA/EAA
restriction, again regardless of sex.
As DPD also affects lipid metabolism14,17 and the IGF1
axis12,14, we also assessed these. Serum triglyceride levels were
lower with dietary AA/EAA restriction, and this was more
pronounced in male than female mice (Supplementary Fig. 4I, J).
Serum IGF1 levels were substantially lower with total AA
restriction, but not with dietary Thr restriction, with dietary
EAA restriction producing an intermediary response, particularly
in male mice (Supplementary Fig. 4K, L).
To reinforce the findings that only certain EAA such as Thr
and Trp are important for the effects of dietary EAA restriction,
we then wanted to confirm the importance of these EAA in
other situations. To this end, we utilised a mouse model with
intestinal and renal neutral amino acid transport deficiency
(i.e., B0AT1/Slc6a19 knockout mouse), which exhibits meta-
bolic features akin to dietary protein/AA restriction22. Initially,
we characterised the hepatic portal vein AA profile, and could
demonstrate that while there were higher levels of certain AA
such as Arg and Lys, there was substantially lower levels of Thr
and Trp (Fig. 5a). In order to test the involvement of these AA
in the phenotype of these mice, we conducted an acute AA add-
back study, and could demonstrate that systemic add-back (by
intraperitoneal administration) of Thr and Trp, but not His and
Phe, could reverse the upregulation of blood plasma FGF21
levels in these mice (Fig. 5b), highlighting the importance of
these two EAA in the response to dietary AA restriction.
Thr restriction promotes metabolic health via liver FGF21. As
we have previously shown that dietary protein or AA dilution can
retard the development of obesity-related metabolic dysfunction,
we then tested whether selective Thr restriction (LT), without
total AA restriction or altered dietary carbohydrate supply, can
mimic these effects in a mouse model of obesity-related metabolic
dysfunction, the New Zealand Obese (NZO) mouse. Of note,
similar to our prior findings of NZO mice subjected to dietary
protein/AA dilution14,49, there was no effects of LT on body mass
development and liver and adipose tissue weights (Supplementary
Fig. 5A, B). However, LT completely retarded the development of
hyperglycaemia (Fig. 5c), reduced hypertriglyceridemia (Fig. 5d),
and increased serum FGF21 levels (Fig. 5e), in this model.
Altogether, these results highlight that dietary Thr is a common
EAA mediating effects of dietary AA restriction across mouse
models, and that dietary Thr restriction can affect positive health
outcomes in obesity.
As FGF21 was commonly affected by dietary EAA restriction
(Figs. 2–5), and liver-derived FGF21 conveys the metabolic
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remodelling with DPD14,24,26 and methionine restriction42, we
tested the requirement of liver-derived FGF21 in the systemic
metabolic remodelling with LT. As such, we administered adeno-
associated viruses to express Cre-recombinase (AAV-CRE) to Fgf21
floxed mice to silence Fgf21 expression/secretion in a liver/
hepatocyte-specific manner. Indeed, serum levels of FGF21 were
absent in groups treated with AAV-CRE (Fig. 6a). Hepatocyte
Fgf21 silencing retarded the depressed feed efficiency with LT
(Fig. 6b), mostly owing to a complete abrogation of the effects on
reduced body mass gain with LT (Supplementary Fig. 6A, B), with
blunted effects of LT feeding on fat tissue (Supplementary Fig. 6C).
In addition, the effects of LT to increase energy expenditure (Fig. 6c
and Supplementary Fig. 6D) and food energy intake (Supplemen-
tary Fig. 6E) were also abrogated with liver Fgf21 silencing. In
congruence, the improved glucose metabolism (Fig. 6d and
Supplementary Fig. 6F, G) and reduced serum triglyceride levels
(Supplementary Fig. 6H) with LT were also abrogated with liver/
hepatocyte Fgf21 loss. In summary, the systemic metabolic
remodelling with LT requires liver-derived FGF21.
Enforced liver Thr biosynthesis reverses Thr restriction effects.
Although EAA systemic metabolic turnover is intimately related
to genome-wide exome EAA abundance54, the major metabolic
fate of EAA may not be for protein synthesis50. Thus, we sought
to test whether it is the inability to synthesise the strictly EAA
that characterises them as the most limiting and thus required for
the effects of DEAR. To this end we produced adeno-associated
viruses to express the yeast Thr biosynthetic enzymes (i.e., Thr1
and Thr4) in the liver hepatocytes of mice and subjected them to
LT. Using high-resolution mass spectrometry, the yeast proteins
THR1 and THR4 were confidently identified in mouse liver
extracts overexpressing THR1 and THR4, but not of those
expressing GFP (Supplementary Table 3 and Supplementary File
2). Liver-specific expression was also confirmed by qPCR.
Importantly, the reduction of liver Thr concentration was
reverted with liver-specific enforcement of de novo threonine
biosynthesis (Supplementary Fig. 7A and Supplementary
Table 4). Strikingly, the effects of dietary Thr restriction on
metabolic efficiency, serum FGF21, and glucose metabolism were
completely reversed by artificially increasing the liver Thr de novo
biosynthesis (Fig. 7a–d and Supplementary Fig. 7B–F).
Discussion
DPD promotes metabolic health by inducing the hepatokine
fibroblast growth factor 21 (FGF21)14,16, but the precise
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Fig. 7 Enforced hepatic threonine biosynthetic capacity reverses the
systemic metabolic effects to dietary threonine restriction. a Feed
efficiency of mice in response to a 3-week treatment with diets containing
18% from amino acids (normal amino acid; NAA; yellow bars) and a diet
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of mice as in (a). c Serum fibroblast growth factor 21 (FGF21) levels of mice
as in (a). d Insulin sensitivity index during fasting (ISI(f)) of mice as in (a).
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nutritional components driving this response are not fully
defined. In particular, in order to keep total caloric supply neutral,
which is an important consideration in diet–phenotype
interactions3,5, another macronutrient source must be con-
comitantly increased. In former studies5,14,24, this was typically
achieved by increasing dietary carbohydrates, which may be an
independent driver of increased FGF2134,35. DPD can also
increase food intake, but particularly on low protein–high-car-
bohydrate diets, this increased food intake is surpassed by
heightened energy expenditure, promoting a situation of systemic
metabolic inefficiency14,24. However, on a low-protein–high-fat
diet, mice gain more body weight4,14, which may4 or may not14,16
promote worsened metabolic health. This weaker response to
differing diluting nutrients in DPD is perhaps due to the absence
of relatively weaker satiating effects of lipids versus protein or
carbohydrate55,56. Nevertheless, pair-feeding studies have shown
that the DPD-driven heightened energy expenditure and FGF21
can be uncoupled from food intake32, indicating that the major
driver of metabolic inefficiency is not due to food energy
ingestion.
Importantly, our studies here (Figs. 1–7), as well as previous
studies of amino acid (AA) restriction23,37, have conclusively
shown that a restriction of dietary protein/AA per se can induce
the systemic metabolic response to DPD. This occurs even when
total dietary AA enrichment is held constant (Figs. 1–7), and total
protein N supply and oxidation is not affected (Fig. 2d). Never-
theless, there are important relationships between total energy
and N intake6,57, and deciphering the roles of certain AAs and
FGF21 in this context will be interesting. On another note, even
though dietary protein as a nutrient can be digested and absorbed
as AA or short peptides, our data reinforce that dietary AA supply
is paramount under conditions of dietary protein restriction.
Importantly, metabolomic studies of postprandial plasma amino
acid levels in Slc6a19 null mice, which mimic the effects of DPD,
also revealed a prominent effect on Thr and Trp when fed
standard laboratory chow58. By contrast, the ablation of intestinal
peptide transport does not mimic the effects of DPD59.
So could restriction of certain AA confer this response? There
are several studies showing that dietary EAA restriction is suffi-
cient to induce many of the responses to DPD20,37. On the other
hand, there are several lines of evidence that restriction of sys-
temic non-EAA (NEAA) supply to the liver influences FGF21 and
systemic metabolism14,46–48. Thus, with the evidence that both
EAA and NEAA supply (i.e., hepatic portal vein) and liver EAA
and NEAA levels are affected by DPD (Fig. 2), we sought to
systemically investigate the role of EAA and NEAA restriction.
Through a series of studies, we empirically determined that EAA,
and in particular the EAA Thr and Trp, are necessary and suf-
ficient to induce the systemic metabolic response to DPD
(Figs. 2–7), independent of total dietary AA supply. Importantly,
this validates a prior study predicting that Thr is the most lim-
iting AA from AA exome matching under a casein-based diet20 as
well as a recent study demonstrating that the hyperphagia due to
dietary casein/AA restriction relates to Thr and/or Trp supply60.
However, here we demonstrate that both Thr and Trp are equally
limiting in the casein-based diet through empirical investigation,
both by dietary AA restriction and by using a genetic model of
AA-transport deficiency (Fig. 5). While this may seem contrary to
those studies which have shown that restriction of certain EAA
such as the branched chain AA (BCAA) or sulfur-containing AA
(SCAA) are sufficient to mimic systemic metabolic response to
DPD37, this may be explained by titration thresholds dictated by
ratios of dietary supply and somatic demand. In particular, with
regard to titration, basing the deprivation levels on the 5%E
casein diet simply identifies those AA most limiting in this nat-
ural protein source, and that if we also restricted an AA to a
theoretical level below which they would be limiting according to
some somatic constraint20, then this would likely trigger a similar
response. Indeed, even though Lys is an abundant AA in the milk
protein casein, it is the most limiting EAA in protein derived
from maize (i.e., zein)61, and the dietary supply of many EAAs
are reduced in health-promoting vegan diets62. Nonetheless, it is
known that certain EAA can be synthesised/spared by metabo-
lism of precursors that can be mobilised within the body and/or
supplied by diet50. In particular, systemic responses to restriction
of the EAA Met can be alleviated by dietary Cys driven Met
sparing63–65. In addition, restriction of all three BCAA, but not
leucine alone, recapitulates many of the features of total AA
restriction21. This metabolic compensation between BCAA is
perhaps explained by that the metabolism of the three BCAA is
linked by a single transaminase reaction66, with rapid in vivo
metabolism of BCAA, of which the liver is a major contributor67,
despite the absence of a BCAA transaminase in hepatocytes66.
Thus, we postulate that if one of the BCAA becomes limiting it
can be spared by the other BCAAs, and their metabolism, within
the tissue and between tissues. In support of the concept of
“metabolic sparing”, liver refurbishment of de novo biosynthesis
of Thr abated the effects of dietary Thr restriction (Fig. 7). Thus
we propose that it is the strictly metabolically EAA, namely Lys,
Thr, and Trp, which have the potential to be most limiting in a
particular diet. Nonetheless, the differences in the sensitivity of
AA restriction requires careful studies of nutritional EAA titra-
tion, especially as our studies were fully based on AA supply from
a single nutritional source (i.e., the milk protein casein). This is a
clear direction for future studies. In addition, further studies are
required to carefully dissect which EAA drive (mal)-adaptive
processes during DPD, and in particular which do so under cir-
cumstances of altered somatic AA metabolism such as age-related
disease, infection, or pregnancy. Furthermore, as our studies were
conducted in mice the relevance of our findings to human
nutritional responses is vague without carefully controlled
nutritional amino acid titration experiments using humans.
Most of the studies here were conducted using young (i.e.,
8 weeks) male mice fed for a short period of time (i.e., 3 weeks).
Thus, this may limit the applicability of the findings, especially
since female mice can respond differently to dietary chal-
lenges51–53 and AA requirements can be different during
growth/maturation versus adulthood50. However, the majority
of the effects of dietary AA restriction seen in young mice (i.e.,
feed efficiency, energy expenditure, food intake, glucose meta-
bolism) were also reflected in older male and female mice, albeit
with female mice responding to a lesser extent (Fig. 4). Of note
however, were the effects of the different AA restriction diets on
lean body mass and skeletal/heart muscle mass with total AA or
EAA restriction lowering lean tissue mass, whereas the low Thr
diet did not. This highlights that a low Thr diet can induce
many of the positive effects of dietary AA restriction while
avoiding some negative side effects such as lean tissue wasting.
On this, similar to that previously shown for dietary protein/AA
dilution14,16,21,49,68, and SCAA or BCAA restriction21,38,42–44,
low Thr feeding also retarded development of obesity-induced
metabolic dysfunction in a mouse model (Fig. 5). Dietary Thr
restriction may thus be an attractive strategy to mimic the
effects of DPD without unwanted caveats, particularly as dietary
Thr is largely metabolised by the intestine69 and thus many
potential undesirable systemic side-effects may be avoided.
Several studies have demonstrated that
systemic14,16,24,25,32,40,44,68 or liver-restricted14,26 Fgf21-loss retards
the downstream metabolic effects of dietary protein/AA restriction.
In particular, these effects are likely to be mediated by central
nervous system FGF21 signalling68, to stimulate nutrient uptake/
oxidation in adipose tissue and heart14,16. Here we extend upon
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these findings and demonstrate that adult, liver-specific FGF21
loss completely abrogates the systemic metabolic remodelling
with dietary Thr restriction (Fig. 6). In addition, given that liver/
hepatocyte-specific restoration of EAA biosynthesis could rescue
effects of EAA restriction (Fig. 7), taken together this reinforces
the prior evidence14 that the liver is the chief anatomical site
“sensing” dietary protein/AA restriction which is logical given its
proximal anatomical position to nutrient absorption.
In conclusion, from studies of mice using a casein-based diets,
the restriction of EAA, particularly Thr and Trp, are sufficient
and necessary to confer the systemic metabolic effects of DPD.
Methods
All unique materials are available from commercial vendors or from the authors
pending material transfer agreements. The data that support the findings of this
study are available from the corresponding author upon reasonable request.
Diets. Diets were purchased either from Specialty Feeds (Perth, Australia; Sup-
plementary Table 1) or Research Diets (NJ, USA; Supplementary Table 2). Study A
(Fig. 1 and Supplementary Fig. 1) was a comparison of diets SF17-180 (20% E from
protein), SF17-175 (5% E from protein), and SF17-176 (5% E from protein and
15% E from amino acids). Study B (Fig. 2a, b) was a comparison of diets D12450B
(20% E protein) and D10062201 (5% E protein). Study C (Fig. 2c–i and Supple-
mentary Fig. 2) was a comparison of amino acid containing diets
A14011601–A14011606. Study D (Fig. 3a–d and Supplementary Fig. 3A–E) was a
comparison of diets A14011601, A14011605, and A16120501–A16120503. Study E
(Supplementary Fig. 3F–I) was a comparison of diets A14011601, A14011605, and
A17020901–A17020903. Study F (Fig. 3e–h and Supplementary Fig. 3J–N) was a
comparison of diets A14011601, A14011605, and A170401301–A170401303. Study
G (Supplementary Fig. 3O–R) was a comparison of diets SF14-162 and SF17-114.
Study H (Fig. 3i–l and Supplementary Fig. 3S–W) was a comparison of diets SF17-
177, SF18-109, and SF17-110. Study I (Fig. 4 and Supplementary Fig. 4) was a
comparison of diets SF17-177, SF18-109, SF19-086, and SF17-179. Study J
(Fig. 5e–g and Supplementary Fig. 5) and study K (Fig. 6 and Supplementary
Fig. 6) was a comparison of diets SF17-177 and SF17-179. Study K (Fig. 7 and
Supplementary Fig. 7) was a comparison of diets SF17-177 and SF18-066.
Recombinant viruses. A control (green fluorescent protein: GFP), Cre-recombi-
nase, yeast (Saccharomyces cerevisiae) threonine 1 (Thr1), or threonine 4 (Thr4)
cDNAs were cloned into AAV genome plasmids for subsequent production of self-
complimentary adeno-associated viruses (AAV) using the three plasmid system.
The genome plasmid encoding either hepatocyte-specific regulated (via LP1-
promoter70,71) GFP, Thr1, or Thr4 was co-transfected with the adenoviral helper
plasmid pDGΔVP and the capsid plasmid p5E18VD2/8-mut6 (aa 589–592: QNTA
to GNRQ; AAV8 to AAV2)72. Purification and quantification of the final vector
stocks was done by density gradient/filtration purification and quantitative real-
time PCR, respectively73.
Mouse experiments. Unless stated otherwise, male mice aged 7 weeks upon
arrival, were acclimated to the local housing facility (12–12 h light–dark cycle,
22–24 °C) for 1 week prior to experimentation and were fed standard rodent chow
(3437, Provimi Kliba, Germany or 8720610, Barastoc, Australia) unless otherwise
indicated. Mice used for experiments were C57Bl/6NCrl mice (#027, Charles River
Laboratories, Germany), C57Bl/6J (Monash University Animal Research Platform,
Clayton, Australia or Animal Resource Centre, Australia). Slc6a19−/− and cor-
responding +/+ littermates22 as well as Fgf21 fl/fl littermate mice74 were also used,
both on C57Bl/6J background. New Zealand Obese mice75, a model of obesity-
induced type 2 diabetes, were also used.
The dietary intervention was identical for nearly all experiments (Figs. 1–3 and
7) and is outlined in Supplementary Fig. 1A. In brief, following acclimation, mice
were placed on diets for 3 weeks with body weight recorded each week and
metabolic cage housing during week 2 with a 5-h fasting bleed (sometimes with a
glucose tolerance test) conducted during week 3 (i.e., day 19–20). Mice were then
humanely euthanised for tissue collection.
To examine the chronic effects of dietary AA restriction on fully developed
mice, 6-month-old male and female C57Bl/6J mice were treated with diets SF17-
177 (NAA), SF18-109 (LAA), SF19-086 (LEAA), and SF17-179 (LT) for a period of
8 weeks. Body weight and composition (ECHO-MRITM 3in1, EchoMRI LLC, USA)
was measured before and at the end of the treatment period. Metabolic cage
housing was completed for 5 days, 1-week after diet initiation. A 5 h fasting bleed
was conducted 7 weeks after diet initiation. At the end of 8 weeks, mice were
humanely euthanised for tissue collection.
For studies on New Zealand Obese mice, mice were obtained at 7 weeks of age
and acclimated to the housing facility. At 8 weeks, they were switched to either diet
SF17-177 (NAA) or SF17-179 (LT) and studies for a further 4 weeks. Mice were
weighed and bled for blood glucose measurement in the random fed state before,
and each week. At the end of 8 weeks, mice were humanely euthanised for tissue
collection.
For liver/hepatocyte-specific Fgf21 silencing experiments (Fig. 6), we conducted
experiments where following acclimation, 7-week-old Fgf21fl/fl mice were
administered a total of 2.5 × 1011 virus particles per mouse via the tail vein. For the
negative control (NC): 2.5 × 1011 GFP-AAV; and for the Cre-recombinase
overexpression studies mice were administered 2.5 × 1011 virus particles each of
CRE-AAV. One week following this time, the dietary intervention was initiated and
continued for 8 weeks with metabolic cage housing during week 2 and a fasting
bleed during week 7. At the end of 8 weeks, mice were humanely euthanised for
tissue collection.
For liver/hepatocyte-specific yTHR1 and yTHR4 expression experiments
(Fig. 7), we conducted experiments where following acclimation, mice were
administered a total of 5 × 1011 virus particles per mouse via the tail vein. For the
negative control (NC): 5 × 1011 GFP-AAV; and for the THR1/4 overexpression
studies mice were administered 2.5 × 1011 virus particles each of yTHR1-AAV and
yTHR4-AAV. One week following this time, the dietary intervention was initiated.
In these studies, the low threonine diets contained homoserine, the substrate of
THR1. Importantly, pilot studies showed no differences in the response to a low
threonine diet with or without supplemented homoserine.
For the experiment involving selective restriction of Met, Thr, and Trp, mice
were placed on one of two experimental diets at 12 weeks of age for 6 weeks. Food
intake was measured weekly and body weights were measured every 2 weeks.
Animals were then humanely euthanised for tissue collection.
Fasting–refeeding experiments were conducted to nutritionally synchronise
mice for metabolomics measurement. As such, cohorts of mice was adapted to a
control or low protein diet for 1 week using diets described14. After this, they were
fasted overnight, and then refed the same diet for 4–5 h following which they were
anesthetised for hepatic portal vein bleeding (cohort 1) or killed by cervical
dislocation for rapid freezing of the liver in situ using a freeze clamp precooled in
LN2 (cohort 2).
We conducted hepatic portal vein bleeding from Slc6a19−/− and
corresponding +/+ littermate mice with blood serum amino acid profiling,
including sample preparation and derivatization, by LC–MS/MS using the EZ:faast
kit (Phenomenex)14. In order to test for the requirement of systemic Thr and Trp
lowering on serum FGF21 in the background of Slc6a19 loss-of-function, we fasted
Slc6a19−/− and corresponding +/+ littermates overnight and then refed mice a
20% EP diet for 2 h, after which we withdrew the food. Upon food withdrawal,
mice were intraperitoneally injected a 0.9% saline solution (Vehicle), or a mixture
of L-threonine and L-tryptophan (6 mg each, 12 mg; ~0.5 mg/g body mass), or a
mixture of L-phenylalanine and L-histidine (6 mg each, 12 mg; ~0.5 mg/g body
mass) and tail vein blood was then collected 4–5 h later.
Animal experiments were conducted according to regional, national, and
continental ethical guidelines and protocols were approved by local regulatory
authorities (Regierungspräsidium Karlsruhe, Germany; Monash University Animal
Ethics Committee, Australia; and University of Sydney Animal Ethics Committee,
Australia) and conformed to ARRIVE guidelines.
Biometric and metabolic phenotyping. The dietary intervention study is outlined
in Supplementary Fig. 1A. Mice were housed in groups of 2–3 unless placed within
the metabolic cages (see below). Body weight was measured before and after the
dietary intervention period and body mass difference was calculated. Indirect
calorimetry and food intake was recorded by individual housing in metabolic
phenotyping system cages (TSE Phenomaster System (TSE Systems, Germany) or
Promethion-M High Definition Multiplexed Respirometry System (Sable Systems
International, USA)). Energy expenditure (W) was estimated using the Weir
equation76 from VO2 and VCO2 measurements (EE (W or J/s)= ((1.44 × (3.94 ×
VO2 (mL/h)+ 1.11 × VCO2 (mL/h))/1000 × 4.196) × 0.28). Feed efficiency was
calculated from the quotient of the change in body mass (mg) and cumulative food
energy intake (kJ) during the metabolic cage housing. To assess whole-body glu-
cose homoeostasis, a 5–6 h fasting blood sample (fasting initiated at ZT3, sampling
at ZT8-9) was collected from the tail vein from which blood glucose (AccuCheck
Aviva) and plasma insulin (80-INSMS, Alpco, USA) was measured. In some stu-
dies, an intraperitoneal glucose tolerance test was conducted immediately following
the fasting blood sample by injection of a fixed dose of 50 mg of D-glucose in 0.9%
saline77 with blood samples drawn for glucose and insulin measurement at selected
times after. In addition, HOMA-IR ((glucose (mM) × insulin (pM))/3857))78 and a
fasting insulin sensitivity index (ISIf) was calculated, ISI(f): 1000/(glucose (mM) ×
insulin (pM)), and are good surrogate indices of whole-body glucose
homoeostasis14,79. The methods for assessment of glucose homoeostasis in mice
were conducted in accordance with published guidelines77,80. Serum FGF21
(MF2100, R&D Systems, USA), urea (Z5030016, Biochain, USA), and triglycerides
(TR0100, Sigma-Aldrich, USA) were also measured from the blood serum samples
upon sacrifice by cervical dislocation between ZT3-5.
Metabolomics. Livers were cryogenically pulverised (cryopulverization) using a
12-well biopulverizer (BioSpec Products, OK, USA, Part number 59012MS)
according to the manufacturer’s instructions. The frozen tissue powder was then
weighed and extracted in 20 µL of extraction solvent (0 °C) per mg of tissue. The
mixture was then briefly vortexed before sonication in an ice-water bath for 10 min
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16568-z
10 NATURE COMMUNICATIONS |         (2020) 11:2894 | https://doi.org/10.1038/s41467-020-16568-z | www.nature.com/naturecommunications
followed by centrifugation (20,000 rcf, 4 °C, 10 min). The supernatant was then
transferred to a mass spectrometry vial for LC–MS analysis. The extraction solvent
consisted of 2:6:1 CHCl3:MeOH:H2O v/v/v with 2 µM CHAPS, CAPS, PIPES, and
TRIS as internal standards. Additionally where quantitative amino acid analysis
was performed, a mixture of stable isotope labelled amino acids were added at a
concentration of 500 pmol of each amino acid per mg liver (Cambridge Isotope
Laboratories PN MSK-A2-1.2).
Plasma (25 µL) was extracted by addition of 200 µL of 1:1 acetonitrile:MeOH v/
v with 1 µM CHAPS, CAPS, PIPES, and TRIS as internal standards at 0 °C.
Samples were then mixed on a vortex mixer for 30 min at 4 °C after which they
were centrifuged (20,000 rcf, 4 °C, 15 min) and the supernatant then transferred to
a mass spectrometry vial for LC–MS analysis.
For LC–MS analysis, samples were analysed by hydrophilic interaction liquid
chromatography coupled to high-resolution mass spectrometry (LC–MS)81. In
brief, the chromatography utilised a ZIC-pHILIC column (column temperature
25 °C) with a gradient elution of 20 mM ammonium carbonate (A) and acetonitrile
(B) (linear-gradient time—%B as follows: 0 min—80%, 15 min—50%, 18 min—5%,
21 min—5%, 24 min—80%, 32 min—80%) on a Dionex RSLC3000 UHPLC
(Thermo). The flow rate was maintained at 300 μL/min. Samples were kept at 4 °C
in the autosampler and 10 μL injected for analysis. The mass spectrometry was
performed at 35,000 resolution (accuracy calibrated to <1 ppm) on a Q-Exactive
Orbitrap MS (Thermo) operating in rapid switching positive (4 kV) and negative
(−3.5 kV) mode electrospray ionisation (capillary temperature 300 °C; sheath gas
50; Aux gas 20; sweep gas 2; probe temp 120 °C). All samples were analysed in
randomised order and with pooled quality control samples analysed regularly
throughout the batch to confirm reproducibility. ∼300 Metabolite standards,
including all reported amino acids, were analysed immediately preceding the batch
to determine accurate retention times to confirm metabolite identification.
For data analysis, untargeted metabolomics data were analysed using the
IDEOM (version 20) workflow with default parameters82. In brief, this involved
peak picking with XCMS83, peak alignment and filtering with mzMatch84 and
further filtering, metabolite identification, and comparative analysis with IDEOM.
Amino acid concentration was determined by the integration of the extracted ion
chromatograms of the amino acids and their corresponding stable isotope labelled
isotopologues in MZmine 2.3285,86. All peaks were inspected and where necessary
the integration parameters altered to insure accurate integrations. Nearly all the
amino acids were detected in both polarities, however we elected to use the negative
mode data for all amino acids except Ala, Arg, Gly, and His where we used positive
mode data. The amino acid concentration was then calculated by comparison of
the peak areas of each amino acid against its corresponding heavy labelled
isotopologue.
Proteomics. The mouse liver tissue was homogenised in liquid nitrogen using a
BioPulverizer and directly solubilised in sodium dodecyl sulfate (SDS) lysis buffer.
The protein concentration was determined using a BCA kit (Thermo Scientific)
and equal amounts of protein were processed for both pooled control (GFP) and
THR1/4-overexpressed mouse liver sample. SDS was removed by chloroform/
methanol precipitation and the proteins were proteolytically digested with trypsin
(Promega) and purified using OMIX C18 Mini-Bed tips (Agilent Technologies)
prior to LC–MS/MS analysis. Using a Dionex UltiMate 3000 RSLCnano system
equipped with a Dionex UltiMate 3000 RS autosampler, an Acclaim PepMap RSLC
analytical column (75 µm × 50 cm, nanoViper, C18, 2 µm, 100 Å; Thermo Scien-
tific) and an Acclaim PepMap 100 trap column (100 µm × 2 cm, nanoViper, C18,
5 µm, 100 Å; Thermo Scientific), the tryptic peptides were separated by increasing
concentrations of 80% ACN/0.1% formic acid at a flow of 250 nL/min for 158 min
and analysed with a QExactive Plus mass spectrometer (Thermo Scientific) using
in-house optimised parameters to maximise the number of peptide identifications.
To obtain peptide sequence information, the raw files were searched with Byonic
v3.0.0 (ProteinMetrics) against a mouse UniProt/SwissProt database that was
appended with the yeast THR1/THR4 protein sequences. Only proteins falling
within a false discovery rate of 1% based on a decoy database were considered for
further analysis.
RNA extraction and analysis. RNA was extracted from tissues using QIAzol and
cDNA was synthesised using the Quantitect Reverse Transcription Kit (Qiagen).
qPCR was conducted using Quantitect Sybr Green qPCR (Qiagen) with the fol-
lowing primers: PrimePCR™ SYBR® Green Assays to yeast Thr1 (qSceCED0001111,
Bio-Rad) and Thr4 (qSceCED0005815, Bio-Rad) as well as mouse Tbp
(QT00198443, Qiagen) as a housekeeping gene.
Statistical analyses. Mice were assigned to groups based upon initial body mass
for counterbalancing. Pre-established criteria for exclusion of mice from study
groups were obvious infections/wounds which would impact on feeding behaviour
as well as metabolic profile. Where possible, analysis of data collection was blinded.
Statistical analyses were performed using t-tests (two-sided), or 2-way analysis
of variance (ANOVA) with or without repeated measures, where appropriate, with
Holm–Sidak-adjusted post-tests. All analyses were carried out with GraphPad
Prism v.7.01 (GraphPad Software, Inc.) or SigmaPlot 14 (Systat Software, Inc.)
software. Statistical details can be found within the figure legends. Differences
between groups were considered significant when P < 0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 1a–i, 2a, b, d–j, 3a–l, 4a–l, 5a–e, 6a–d, and 7a–d and
Supplementary Figs. 1B–F, 2A–L, 3A–W, 4A–L, 5A, B, 6A–H, and 7A–F are provided as
a Source Data file. The annotated metabolomics and proteomics data can be found
within Supplementary Datasets 1 and 2, respectively. The metabolomics data is available
at the NIH Common Fund’s National Metabolomics Data Repository (NMDR) website,
the Metabolomics Workbench, https://www.metabolomicsworkbench.org where it has
been assigned Project ID PR000917. The data can be accessed directly via its Project DOI:
10.21228/M8568J. The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE87 partner repository with the dataset
identifier PXD018205.
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